Updates from Clinical Sequencing of 2,138 Bone and Soft Tissue Sarcomas

This episode is sponsored by BTG Speciality Pharmaceuticals. BTG provides rescue medicines typically used in emergency rooms and intensive care units to treat patients for whom there are limited treatment options. They are dedicated to delivering quality medicines that make a real difference to patients and their families through the development, manufacture, and commercialization of pharmaceutical products. Their current portfolio of antidotes counteracts certain snake venoms and the toxicity associated with some heart and cancer medications. --- Benjamin Nacev, MD PhD is a physician-scientist with an interest in sarcoma biology. His work focuses on understanding the causes of sarcomas with a goal of developing new treatments. Dr. Nacev completed his MD and PhD training at the Johns Hopkins University School of Medicine, where he also trained in Internal Medicine. He moved to Memorial Sloan Kettering where he completed his Medical Oncology Fellowship and later joined the faculty before moving to the University of Pittsburgh School of Medicine and the UPMC Hillman Cancer Center. - What We Do at MIB Agents: PROGRAMS: ✨ End-of-Life MISSIONS ✨ Gamer Agents ✨ Agent Writers ✨ Prayer Agents ✨ Healing Hearts - Bereaved Parent Support ✨ Ambassador Agents - Peer Support ✨ Warrior Mail ✨ Young Adult Survivorship Support Group ✨  EDUCATION for physicians, researchers and families: ✨ OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma ✨ MIB Book: Osteosarcoma: From our Families to Yours ✨ RESEARCH: Annual MIB FACTOR Research Conference ✨ Funding $100,000 annually for OS research ✨ MIB Testing & Research Directory ✨ The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. 🔗 https://www.mibagents.org​ Help support MIB Agents, Donate here https://www.mibagents.org/?form=donate ✨✨SUBSCRIBE for all the Osteosarcoma Intel ✨✨